Varda Space Industries<\/b> raised a $187 million Series C round to scale the company\u2019s work to build in-space pharmaceutical labs and hypersonic reentry test capabilities. <\/p>\n
Varda has completed three launch and re-entry missions \u2014 returning two capsules already this year, one in February and another in May. The missions have tested pharmaceutical properties in space and also carried tests for hypersonic reentry. <\/p>\n
Varda is working to scale and commercialize in-space pharmaceutical manufacturing. The company noted it is scaling up in pharmaceutical talent and has hired a team including structural biologists and crystallization scientists. <\/p>\n
\u201cWith this capital, Varda will continue to increase our flight cadence and build out the pharmaceutical lab that will deliver the world\u2019s first microgravity-enabled drug formulation,\u201d Varda CEO Will Bruey said in a release. <\/p>\n
Natural Capital and Shrug Capital led the funding round, with participation from Founders Fund, Peter Thiel, Khosla Ventures, Caffeinated Capital, Lux Capital, and Also Capital.<\/p>\n
Natural Capital investor Ravi Tanuku, who joined the board with this raise, highlighted the company\u2019s potential in hypersonics and pharmaceuticals, particularly in microgravity drug crystallization in a post about the investment. \u201cWe believe Varda sits at the intersection of national-security need and pharmaceutical innovation \u2014 an uncommon combination with significant strategic and financial potential,\u201d Tanuku wrote. <\/p>\n","protected":false},"excerpt":{"rendered":"
Varda Space Industries raised a $187 million Series C round to scale the company\u2019s work to build in-space pharmaceutical labs and hypersonic reentry test capabilities. Varda has completed three launch and re-entry missions \u2014 returning two capsules already this year, one in February and another in May. The missions have tested pharmaceutical properties in space […]<\/p>\n","protected":false},"author":1,"featured_media":48839,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-48838","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts\/48838"}],"collection":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/comments?post=48838"}],"version-history":[{"count":0,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts\/48838\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/media\/48839"}],"wp:attachment":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/media?parent=48838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/categories?post=48838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/tags?post=48838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}